These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16703728)

  • 41. Urine Biomarkers for the Diagnosis of Bladder Cancer: a Network Meta-Analysis.
    Dong Y; Zhang T; Li X; Yu F; Yu H; Shao S
    Urol J; 2021 Sep; 18(6):623-632. PubMed ID: 34585369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study.
    Pichler R; Tulchiner G; Fritz J; Schaefer G; Horninger W; Heidegger I
    Int J Med Sci; 2017; 14(9):811-819. PubMed ID: 28824318
    [No Abstract]   [Full Text] [Related]  

  • 43. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
    Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
    Raitanen MP;
    World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: a systematic review.
    Soorojebally Y; Neuzillet Y; Roumiguié M; Lamy PJ; Allory Y; Descotes F; Ferlicot S; Kassab-Chahmi D; Oudard S; Rébillard X; Roy C; Lebret T; Rouprêt M; Audenet F
    World J Urol; 2023 Feb; 41(2):345-359. PubMed ID: 36592175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy].
    Gutiérrez Baños JL; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Villanueva Peña A; Gutíerrez García R; De Diego Rodríguez E; Rado Velázquez MA
    Arch Esp Urol; 1998 Oct; 51(8):778-82. PubMed ID: 9859583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder.
    Irani J; Desgrandchamps F; Millet C; Toubert ME; Bon D; Aubert J; Le Duc A
    Eur Urol; 1999 Feb; 35(2):89-92. PubMed ID: 9933800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative analysis of sensitivity to blood in the urine for urine-based point-of-care assays (UBC rapid, NMP22 BladderChek and BTA-stat) in primary diagnosis of bladder carcinoma. Interference of blood on the results of urine-based POC tests.
    Lüdecke G; Pilatz A; Hauptmann A; Bschleipfer T; Weidner W
    Anticancer Res; 2012 May; 32(5):2015-8. PubMed ID: 22593481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.
    Kundal VK; Pandith AA; Hamid A; Shah A; Kundal R; Wani SM
    Asian Pac J Cancer Prev; 2010; 11(5):1279-82. PubMed ID: 21198277
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
    Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
    Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The BTA stat test in the follow-up for bladder cancer].
    Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
    Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma.
    Xia CS; Fan CH; Su M; Wang QS; Bao HZ
    Dis Markers; 2020; 2020():3424039. PubMed ID: 32454904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms.
    Murphy WM; Rivera-Ramirez I; Medina CA; Wright NJ; Wajsman Z
    J Urol; 1997 Dec; 158(6):2102-6. PubMed ID: 9366322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urine markers for bladder cancer surveillance: a systematic review.
    van Rhijn BW; van der Poel HG; van der Kwast TH
    Eur Urol; 2005 Jun; 47(6):736-48. PubMed ID: 15925067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer.
    Lotan Y; Shariat SF; Schmitz-Dräger BJ; Sanchez-Carbayo M; Jankevicius F; Racioppi M; Minner SJ; Stöhr B; Bassi PF; Grossman HB
    Urol Oncol; 2010; 28(4):441-8. PubMed ID: 20610281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
    Zippe C; Pandrangi L; Agarwal A
    J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
    Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.